Full-scale entry into the medical foods market through the acquisition of Cambrooke
First written in FY2018-Q2. 2 of 4 entries say "Advanced", first in FY2021. Latest entry: FY2025.
The whole theme swung hardest in 2024: 1 of 6 companies on the "Worse" side.
4 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「The Company also completed an investment in Enhanced Medical Nutrition, a Canadian surgical nutrition start-up based in Ontario. Through this investment, the Company will strengthen efforts to further address patients’ nutritional challenges, in addition to the existing medical food businesses operated by its consolidated subsidiary Ajinomoto Cambrooke, based in the United States, and Nualtra, which operates from the United Kingdom and Ireland.」
In addition to Cambrooke and Nualtra, the Company invested in Enhanced Medical Nutrition, broadening the geographic and functional scope of its medical food business. - FY2021AdvancedAnnual report
「In December 2020, the Company made Nualtra, an Irish supplement company, a subsidiary in connection with its medical food business. Together with Ajinomoto Cambrooke, the business has bases in the United States and Europe. By applying the “taste design technology®” and application technologies developed through the food and amino science businesses, as well as its knowledge of the physiological functions of amino acids, the Company will contribute to improving users’ quality of life, including by addressing dietary restrictions caused by disease and nutritional deficiencies associated with aging.」
In addition to Cambrooke, the Company made Nualtra a subsidiary in December 2020, expanding its medical food business with bases in the United States and Europe. - FY2018-Q3RestatedAnnual report
「Through its consolidated subsidiary Ajinomoto North America, the Company acquired an additional 98.4% of the shares of Cambrooke Therapeutics, Inc., a U.S. medical food company, on 8 November 2017, making it a wholly owned subsidiary. The Group had previously sold amino acids as ingredients for the medical food market, but this acquisition marks its full-scale entry into the market. By applying the Group’s scientific knowledge of the nutritional and physiological functions of amino acids, its “taste design technology” and food application technology to Cambrooke’s business, the Group will contribute to improving the quality of life of patients with metabolic disorders by providing more comprehensive nutrition.」
The Company reconfirmed its acquisition of an additional 98.4% of Cambrooke and its conversion into a wholly owned subsidiary, as well as its policy of entering the medical food market in earnest by leveraging its knowledge of amino acids and taste design technology. - FY2018-Q2First statedAnnual report
「Through Ajinomoto North America, the Company acquired an additional 98.4% of the shares of Cambrooke Therapeutics, Inc., a U.S. medical food company, on 8 November 2017, making it a wholly owned subsidiary. The Company had previously sold amino acids as ingredients for the medical food market, but this acquisition marks its full-scale entry into the market. By applying the Company’s scientific knowledge of the nutritional and physiological functions of amino acids, its “taste design technology” and food application technology to Cambrooke’s business, the Company will provide more comprehensive nutrition to patients with metabolic disorders.」
The Company acquired an additional 98.4% of Cambrooke’s shares on 8 November 2017, making it a wholly owned subsidiary, and announced its full-scale entry into the medical food market by leveraging its knowledge of amino acids and taste design technology. The purchase consideration was US$63 million (¥7,269 million).